Additional file 8: Fig. S1. Cumulative lipids composition.

Additional file 9: Fig. S2. Multivariate analysis of the transcriptome in B. gargarizans at different growth stages. (A) The degree of dispersion of the FPKM distribution. The horizontal axis is the sample name, and the vertical axis is for log10(FPKM+1). Box plot elements denote maximum, third quartile, median, first quartile, and minimum. (B) Heatmap for Pearson correlation coefficients (PCC) between samples. The horizontal axis represents the sample name, the vertical axis represents the corresponding sample...

Additional file 1: Figure S1. Pan-cancer analysis of ACE2 expression in tumor and para-tumor tissues in the TCGA database. Significance was calculated with Student’s t-test. ns-P>0.05, *P<0.05, **P<0.01, ***P<0.001, ****P < 0.0001. Figure S2. Pan-cancer analysis of the correlations between ACE2 and immunological features. (A) Correlations between ACE2 and 122 immunomodulators (chemokines, receptors, MHC and immunostimulators). The color reveals the correlation coefficient. The asterisks reveal statistical differences assessed by Pearson analysis. (B) Correlations between ACE2...

Additional file 1. Figure S1: Mendelian error rate of all families. Figure S2: The number of de novo mutations in probands and siblings followed Poisson distribution. Figure S3: Gene (protein synthesis) expression in different brain regions at various periods. Figure S4: Gene (energy) expression in different brain regions at various periods. Figure S5: Gene (pressure) expression in different brain regions at various periods. Figure S6: Gene (amino acid) expression in different brain regions at various...

Additional file 1: Fig. S1. M Molecular docking results of i) the positive-control ligand tofacitinib in the binding sites of JAK3, ii) SD-36 in the binding sites of STAT3, iii) S1P and ML056 (W146) in the binding sites of S1PR1 (A), iv) ML385 in the binding sites of Nrf2, nivolumab in the binding sites of PD-1, and v) BMS-202 in the binding sites of PD-L1 (B) with the lowest calculated binding energy conformations. In the...

Additional file 1. Table S1. Rice importins retrieved from Rice Genome Annotation Project databases. Table S2. Early characterizations of OsIMPα1a-edited (OsIMPα1a-ED) and OsIMPα1b-edited (OsIMPα1b-ED) rice lines. Table S3. Information on genes tested and primers used in this study.

Supplementary Material 1. Supplementary Table 1. Transtheoretical Model and stages of change-oriented lifestyle intervention strategies and measures for simple fatty liver disease patients. Supplementary Table 2. Comparison of healthy behavior levels of the 2 groups (controls vs. transtheoretical model and stages of change) before and after intervention.

Additional file 1: Fig. S1. Lung cancer cell lines with RB1 mutations are resistant to CDK4/6 inhibitor, Fig. S2. Sensitive biomarkers interacted with CHEK1 in large intestine cancer cell lines, Fig. S3. Resistant biomarkers interacted with CHEK1 in lung cancer cell lines, Fig. S4. Functional analysis of the CRs genetic interaction, Fig. S5. Differential chromatin accessibility for CSL interactions, Fig. S6. Differential chromatin accessibility for CSV interactions, Fig. S7. TUBA1C subnetwork in drug related CSL...

Supplementary Material 1

Supplementary Material 1

Supplemental Document

Additional file 1: Figure S1. Up-regulated intact N-glycopeptide ALNSSNTER. Figure S2. Up-regulated intact N-glycopeptide DGVATNVCPR.

Additional file 1: Figure S1. Up-regulated intact N-glycopeptide ALNSSNTER. Figure S2. Up-regulated intact N-glycopeptide DGVATNVCPR.

Supplemental material, sj-docx-5-taj-10.1177_20406223221143245 for Chest X-ray features facilitate screening for pulmonary hypertension caused by fibrosing mediastinitis by Mingfang Zhou, Bo Li, Yaling Chen, Aqian Wang, Yining Zhu, Yu Li, Hongling Su, Jingchun Fan, Yan Zhang and Yunshan Cao in Therapeutic Advances in Chronic Disease

Additional file 11. Fig. S3. The prioritized genes overlapping between the four tools.

Supplementary Material 5: Table S3: The risk of bias for case-control/cross-sectional studies by the Newcastle-Ottawa scale (NOS)

Supplementary Material 5: Table S3: The risk of bias for case-control/cross-sectional studies by the Newcastle-Ottawa scale (NOS)

Supplementary Material 6: PRISMA 2020 Checklist

Additional file 9. Fig. S2. Interaction analyses of prioritized genes by different tools.

Additional file 10: Fig. S3. GO enrichment bubble diagram (G31 vs. G38, G38 vs. G42, G42 vs. G46). (A) and (B) showed the top 30 pathways of significant enrichment of the upregulated and downregulated DEGs on GO for G31 vs. G38, (C) and (D) showed for G38 vs. G42, and (E) and (F) showed for G42 vs. G46.

Additional file 12: Fig. S5. Enrichment analysis of DEGs for B. gargarizans metamorphosis. The top 30 GO terms and pathways of significant enrichment for the (A and B) upregulated DEGs and (C and D) downregulated DEGs. The y-axis corresponds to the GO term or KEGG pathway, the x-axis corresponds to the EnrichmentScore, and the size of the point corresponds to the number of differential genes in the term or pathway.

Additional file 13: Fig. S6. Enrichment analysis of differential lipid-related DEGs. (A) showed the top 30 GO terms of significant enrichment of the differential lipid-related DEGs on GO;(B) showed the top 30 pathways of significant enrichment of the differential lipid-related DEGs on KEGG.

Additional file 9: Tables S1–S7.

Waning of neutralizing titres along with decline of protection efficacy after the second dose of COVID-19 vaccines was observed, including China-made inactivated vaccines. Efficacy of a heterologous boosting using one dose of a recombinant SARS-CoV-2 fusion protein vaccine (V-01) in inactivated vaccine-primed population was studied, aimed to restore the immunity. A randomized, double-blind and placebo-controlled phase III trial was conducted in healthy people aged 18 years or older in Pakistan and Malaysia. Each eligible participant...

The present work aims to prove the concept of tumor-targeted drug delivery mediated by platelets. Doxorubicin (DOX) attached to nanodiamonds (ND-DOX) was investigated as the model payload drug of platelets. In vitro experiments first showed that ND-DOX could be loaded in mouse platelets in a dose-dependent manner with a markedly higher efficiency and capacity than free DOX. ND-DOX-loaded platelets (Plt@ND-DOX) maintained viability and ND-DOX could be stably held in the platelets for at least 4...